Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.61 |
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | PPARA | Q07869 | 1/20 | 0.61 |
| ▸ | MLYCD | O95822 | 2/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455877 | 1.00 | LSS (0.69) | LSSMTORMAPK14EPHX2PPARG | |
| SCHEMBL9416580 | 0.88 | HDAC6 (0.64) | EPHX2KDM1AHDAC1NR1H4HDAC3 | |
| SCHEMBL20477562 | 0.87 | L3MBTL1 (0.69) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL6572354 | 0.87 | HDAC6 (0.72) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL3158764 | 0.86 | EPHX2 (0.73) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL20477571 | 0.86 | MEN1 (0.73) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL507529 | 0.86 | LSS (0.68) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL13947580 | 0.86 | LSS (0.72) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL11979758 | 0.85 | MAPK14 (0.76) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL2634030 | 0.85 | MAPK14 (0.76) | LSSMAPK14EPHX2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509429-B2 | Hydroxybenzamide derivatives and methods of use in treating diabetes | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230348396-A1 | HYDROXYBENZAMIDE DERIVATIVES AND METHODS OF USE IN TREATING DIABETES | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-11-02 | — | — | US | disclosed |
| CN-101230033-B | New azabicycloalkane derivatives, preparing method and medicament combination containing the same | SERVIER LAB | 2011-03-09 | — | — | CN | disclosed |
| CN-100577160-C | Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same | SERVIER LAB | 2010-01-06 | — | — | CN | disclosed |
| US-7576120-B2 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-08-18 | — | — | US | disclosed |
| CN-101230033-A | New azabicycloalkane derivatives, preparing method and medicament combination containing the same | SERVIER LAB (FR) | 2008-07-30 | — | — | CN | disclosed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
| CN-1921848-A | Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2007-02-28 | — | — | CN | disclosed |
| EP-1720544-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005089747-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | LSS 2848/4885MTOR 1758/4885MAPK14 4091/4885 |
| US-12509429-B2 | Hydroxybenzamide derivatives and methods of use in treating diabetes | DBH, IAPP, HSPA5 | LSS 4589/4885MTOR 2221/4885MAPK14 3346/4885 |
| US-20230348396-A1 | HYDROXYBENZAMIDE DERIVATIVES AND METHODS OF USE IN TREATING DIABETES | HSPA5, IAPP, TFEB | LSS 3710/4885MTOR 922/4885MAPK14 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.